Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06412497
Status:
RECRUITING
Last Update Posted:
2024-06-10
First Post:
2024-05-09
Brief Title:
MT2023-20 Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure
Sponsor:
Masonic Cancer Center University of Minnesota
Organization:
Masonic Cancer Center University of Minnesota
Study Overview
Official Title:
MT2023-20 Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase II trial of a reduced intensity conditioned RIC allogeneic hematopoietic cell transplant HCT with post-transplant cyclophosphamide PTCy for idiopathic severe aplastic anemia SAA paroxysmal nocturnal hemoglobinuria PNH acquired pure red cell aplasia aPRCA or acquired amegakaryocytic thrombocytopenia aAT utilizing population pharmacokinetic popPK-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age presence of myelodysplasia andor clonal hematopoiesis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None